

Mohamed Abou El-Enein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8571550/publications.pdf>

Version: 2024-02-01

35
papers

1,315
citations

361413

20
h-index

395702

33
g-index

37
all docs

37
docs citations

37
times ranked

1443
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity of CAR T cells in cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 379-393.	27.6	128
2	Overcoming Challenges Facing Advanced Therapies in the EU Market. <i>Cell Stem Cell</i> , 2016, 19, 293-297.	11.1	114
3	Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. <i>Stem Cells Translational Medicine</i> , 2018, 7, 676-685.	3.3	114
4	Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 342-355.	27.6	113
5	Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. <i>BMJ, The</i> , 2020, 371, m3734.	6.0	101
6	Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. <i>Blood Cancer Discovery</i> , 2021, 2, 408-422.	5.0	84
7	Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. <i>Trends in Biotechnology</i> , 2020, 38, 1099-1112.	9.3	68
8	Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. <i>Cytotherapy</i> , 2013, 15, 362-383.	0.7	57
9	CAR T-cell product performance in haematological malignancies before and after marketing authorisation. <i>Lancet Oncology, The</i> , 2020, 21, e104-e116.	10.7	57
10	Telbivudine in chronic lymphocytic myocarditis and human parvovirus <sc>B19</sc> transcriptional activity. <i>ESC Heart Failure</i> , 2018, 5, 818-829.	3.1	36
11	COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a+. <i>Molecular Therapy</i> , 2020, 28, 2691-2702.	8.2	35
12	Putting a price tag on novel autologous cellular therapies. <i>Cytotherapy</i> , 2016, 18, 1056-1061.	0.7	32
13	Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 269-279.	4.1	29
14	The business case for cell and gene therapies. <i>Nature Biotechnology</i> , 2014, 32, 1192-1193.	17.5	28
15	Strategies for Derisking Translational Processes for Biomedical Technologies. <i>Trends in Biotechnology</i> , 2017, 35, 100-108.	9.3	26
16	Cell and Gene Therapy Trials: Are We Facing an "Evidence Crisis"? <i>EClinicalMedicine</i> , 2019, 7, 13-14.	7.1	26
17	Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. <i>Molecular Therapy</i> , 2018, 26, 1172-1176.	8.2	25
18	Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. <i>Cell Stem Cell</i> , 2017, 21, 427-430.	11.1	24

#	ARTICLE	IF	CITATIONS
19	A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends in Molecular Medicine, 2014, 20, 632-642.	6.7	23
20	Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports, 2021, 16, 1435-1445.	4.8	23
21	The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage?. Trends in Biotechnology, 2019, 37, 120-123.	9.3	20
22	Deciphering the EU clinical trials regulation. Nature Biotechnology, 2016, 34, 231-233.	17.5	19
23	Accelerating Patients' Access to Advanced Therapies in the EU. Molecular Therapy - Methods and Clinical Development, 2017, 7, 15-19.	4.1	19
24	The path to successful commercialization of cell and gene therapies: empowering patient advocates. Cytotherapy, 2017, 19, 293-298.	0.7	18
25	Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Molecular Therapy, 2022, 30, 2298-2314.	8.2	16
26	Clinical Development of Cell Therapies: Setting the Stage for Academic Success. Clinical Pharmacology and Therapeutics, 2017, 101, 35-38.	4.7	14
27	Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation. Advanced Drug Delivery Reviews, 2018, 136-137, 97-104.	13.7	14
28	Evidence generation and reproducibility in cell and gene therapy research: A call to action. Molecular Therapy - Methods and Clinical Development, 2021, 22, 11-14.	4.1	13
29	Post-marketing safety and efficacy surveillance of cell and gene therapies in the EU: A critical review. Cell & Gene Therapy Insights, 2019, 5, 1505-1521.	0.1	12
30	Gene therapy: a possible future standard for HIV care. Trends in Biotechnology, 2015, 33, 374-376.	9.3	8
31	Detection of SARS-CoV-2-specific memory B cells to delineate long-term COVID-19 immunity. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2595-2599.	5.7	7
32	Linking Scattered Stem Cell-Based Data to Advance Therapeutic Development. Trends in Molecular Medicine, 2019, 25, 8-19.	6.7	6
33	Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies. Molecular Therapy, 2020, 28, 2108-2110.	8.2	4
34	The Value of CAR-T-cell Immunotherapy in Cancer. , 2022, , 231-234.		2
35	Clinical translation of viral vectors for gene therapies and beyond. Cell & Gene Therapy Insights, 2016, 2, 507-511.	0.1	0